Halozyme Therapeutics (HALO) Earnings Date, Estimates & Call Transcripts $59.38 -1.24 (-2.05%) Closing price 05/6/2025 04:00 PM EasternExtended Trading$62.81 +3.43 (+5.77%) As of 05:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Halozyme Therapeutics Earnings Summary Latest Q1 2025 Earnings DateMay. 6EstimatedConsensus EPS (May. 6) $0.98 Actual EPS (May. 6) $1.11 Beat By $0.13 Actual Revenue (May. 6) $264.86MHalozyme Therapeutics issued Q1 2025 earnings on May 6, 2025, reporting an EPS of $1.11, which beat the consensus estimate of $0.98 by $0.13. Quarterly revenue rose 35.2% year-over-year to $264.86 million, above analysts' expectations of $231.21 million. With a trailing EPS of $3.43 and a P/E Ratio of 17.31, Halozyme Therapeutics' earnings are expected to grow 31.50% next year, from $4.73 to $6.22 per share. Q1 2025 Earnings ResourcesQ1 2025 Earnings Report Get Halozyme Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Halozyme Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataHALO Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.HALO Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Halozyme Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany EPS GuidanceCompany Revenue GuidanceQ1 20252$0.88$0.93$0.91Q2 20252$1.04$1.09$1.07Q3 20252$1.31$1.41$1.36Q4 20252$1.58$1.66$1.62 FY 2025 8 $4.81 $5.09 $4.95 Q1 20261$1.30$1.30$1.30Q2 20261$1.42$1.42$1.42Q3 20261$1.56$1.56$1.56Q4 20261$1.71$1.71$1.71 FY 2026 4 $5.99 $5.99 $5.99 Q1 20271$1.83$1.83$1.83 Halozyme Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025$0.98$1.11+$0.13$0.93$231.21M$264.86M2/18/2025Q4 2024$1.17$1.19+$0.02$1.06$285.74M$298.01M8/6/2024Q2 2024$0.73$0.91+$0.18$0.98$204.94M$231.40M5/7/2024Q1 2024$0.64$0.71+$0.07$0.82$201.72M$195.88M2/20/2024Q4 2023$0.77$0.75 -$0.02$0.85$235.25M$230.04M11/6/2023Q3 2023$0.67$0.69+$0.02$0.77$219.47M$216.03M8/8/2023Q2 2023$0.59$0.68+$0.09$0.80$201.91M$221.04M5/9/2023Q1 2023$0.44$0.43 -$0.01$0.57$174.20M$162.14M Halozyme Therapeutics Earnings - Frequently Asked Questions When did Halozyme Therapeutics announce their last quarterly earnings? Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earning data on Tuesday, May 6, 2025. Learn more on HALO's earnings history. What guidance has Halozyme Therapeutics issued on next quarter's earnings? Halozyme Therapeutics issued an update on its FY 2025 earnings guidance on Tuesday, May, 6th. The company provided earnings per share guidance of 5.300-5.700 for the period, compared to the consensus earnings per share estimate of 5.000. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion. Did Halozyme Therapeutics beat their earnings estimates last quarter? In the previous quarter, Halozyme Therapeutics (NASDAQ:HALO) reported $1.11 earnings per share (EPS) to beat the analysts' consensus estimate of $0.98 by $0.13. Learn more on analysts' earnings estimate vs. HALO's actual earnings. How much revenue does Halozyme Therapeutics generate each year? Halozyme Therapeutics (NASDAQ:HALO) has a recorded annual revenue of $1.02 billion. How much profit does Halozyme Therapeutics generate each year? Halozyme Therapeutics (NASDAQ:HALO) has a recorded net income of $281.59 million. HALO has generated $3.43 earnings per share over the last four quarters. What is Halozyme Therapeutics's price-to-earnings ratio? Halozyme Therapeutics (NASDAQ:HALO) has a trailing price-to-earnings ratio of 17.31 and a forward price-to-earnings ratio of 12.55. The price/earnings-to-growth ratio is 0.42. What is Halozyme Therapeutics's EPS forecast for next year? Halozyme Therapeutics's earnings are expected to grow from $4.73 per share to $6.22 per share in the next year, which is a 31.50% increase. More Earnings Resources from MarketBeat Related Companies BIIB Earnings Date UTHR Earnings Date INCY Earnings Date BMRN Earnings Date EXEL Earnings Date NBIX Earnings Date EXAS Earnings Date RGEN Earnings Date MDGL Earnings Date IONS Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Palantir Stock Drops Despite Stellar Earnings: What's Next?Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?Warning or Opportunity After Super Micro Computer's EarningsAmazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousRocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 This page (NASDAQ:HALO) was last updated on 5/7/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy HALO Stock Free HALO Stock Alerts